Updates and trends in the treatment of major depressive disorder

Journal of Clinical Psychiatry

Volumn 75, Issue 12, 2014, Pages 1419-1421

  Papakostas, George I ^a   Ionescu, Dawn F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKS 5461; ANTIDEPRESSANT AGENT; CITALOPRAM; DEXMECAMYLAMINE; EDIVOXETINE; ESCITALOPRAM; KETAMINE; LANICEMINE; LISDEXAMFETAMINE; MECAMYLAMINE; MIDAZOLAM; MILNACIPRAN; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VORTIOXETINE;

ADJUVANT THERAPY; ANTIDEPRESSANT ACTIVITY; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SOCIAL PSYCHOLOGY; TREATMENT RESISTANT DEPRESSION; TREND STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG COMBINATION; MULTIMODALITY CANCER THERAPY; TRENDS;

ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84925229817     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14ac09610     Document Type: Article

References (36)

1. Whiteford HA, et al. Lancet. 2013;382(9904):1575-1586.
2. Kinch MS, et al. Trends in pharmaceutical targeting of clinical indications: 1930-2013 [published online ahead of print May 29, 2014]. Drug Discov Today.
3. Kesselheim AS, Darrow JJ. N Engl J Med. 2014;370(26):e39.
4. Hyman SE. Sci Transl Med. 2012;4(155):155cm11.
5. Sanchez C, et al. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data [published online ahead of print July 9, 2014]. Pharmacol Ther.
6. Pearce EF, Murphy JA. Ann Pharmacother. 2014;48(6):758-765.
7. Katona C, et al. Int Clin Psychopharmacol. 2012;27(4):215-223.
8. McIntyre RS, et al. Int J Neuropsychopharmacol. 2014;17(10):1557-1567.
9. Jacobsen P, et al. Randomized, double-blind, head-to-head, flexible-dose study of vortioxetine vs escitalopram in sexual functioning in adults with well controlled major depressive disorder experiencing treatment-emergent sexual dysfunction. Presented at the 29th CINP World Congress of Neuropsychopharmacology; June 25, 2014; Vancouver, BC, Canada. Abstract LP-03-018.
10. Garnock-Jones KP. CNS Drugs. 2014;28(9):855-874.
11. Montgomery SA, et al. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials [published online ahead of print June 5, 2014]. CNS Spectr.
12. Sambunaris A, et al. Int Clin Psychopharmacol. 2014;29(4):197-205.
13. Citrome L. Int J Clin Pract. 2013;67(11):1089-1104.
14. Trivedi MH, et al. J Clin Psychiatry. 2013;74(8):802-809.
15. Ionescu DF, et al. Prim Care Companion CNS Disorders. 2014;16(3):doi:10.4088/PCC.13r01621.
16. Shire reports top-line results from two phase 3 studies for Vyvanse (lisdexamfetamine dimesylate) capsules (CII) as an adjunctive treatment for adults with major depressive disorder [press release]. Basingstoke, UK: Shire; February 6, 2014. http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=921.
17. Ball S, et al. J Affect Disord. 2014;167:215-223.
18. Lilly announces edivoxetine did not meet primary endpoint of phase III clinical studies as add-on therapy for major depressive disorder [press release]. Indianapolis, IN: Eli Lilly; December 5, 2013. http://lilly.mediaroom.com/index.php?s=9042&item=137263.
19. Janowsky DS, Overstreet DH. The Role of Acetylcholine Mechanisms in Mood Disorders. New York, NY: Raven Press; 1995.
20. Furey ML, Drevets WC. Arch Gen Psychiatry. 2006;63(10):1121-1129.
21. Shytle RD, et al. Mol Psychiatry. 2002;7(6):525-535.
22. Lindsley CW. ACS Chem Neurosci. 2010;1(8):530-531.
23. Vieta E, et al. Eur Neuropsychopharmacol. 2014;24(4):564-574.
24. Thase ME, et al. Am J Psychiatry. 2007;164(5):739-752.
25. Wiles N, et al. Lancet. 2013;381(9864):375-384.
26. Berman RM, et al. Biol Psychiatry. 2000;47(4):351-354.
27. Sos P, et al. Neuroendocrinol Lett. 2013;34(4):287-293.
28. Zarate CA Jr, et al. Arch Gen Psychiatry. 2006;63(8):856-864.
29. Murrough JW, et al. Am J Psychiatry. 2013;170(10):1134-1142.
30. Lapidus KA, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder [published online ahead of print April 3, 2014]. Biol Psychiatry.
31. Sanacora G, et al. Mol Psychiatry. 2014;19(9):978-985.
32. Zarate CA Jr, et al. Biol Psychiatry. 2013;74(4):257-264.
33. Berrocoso E, et al. Curr Pharm Des. 2009;15(14):1612-1622.
34. Garriock HA, et al. Am J Psychiatry. 2010;167(5):565-573.
35. Fava M, et al. Psychother Psychosom. 2003;72(3):115-127.
36. Alkermes announces positive results from phase 2 clinical study of ALKS 5461 for major depressive disorder [press release]. Dublin, Ireland: Alkermes; April 17, 2013. http://investor.alkermes.com/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=1807510.